里昂发表研究报告,对中资医药股最新评级及目标价如下: 股份│投资评级│目标价(港元) 相关内容《大行》大摩降国药(01099.HK)目标价至28元 评级「增持」中生制药(01177.HK) +0.100 (+3.876%) 沽空 $3.31千万; 比率 15.753% │买入│14.17元石药(01093.HK) +0.170 (+2.810%) 沽空 $2.93千万; 比率 11.676% │买入│23.37元三生制药(01530.HK) +0.100 (+1.745%) 沽空 $60.42万; 比率 2.035% │买入│17.43元复星医药(02196.HK) +0.100 (+0.850%) 沽空 $8.21百万; 比率 24.196% │跑输大市│23.53元翰森制药(03692.HK) +0.460 (+2.815%) 沽空 $1.84千万; 比率 23.109% │跑赢大市│30.77元中国同辐(01763.HK) +0.020 (+0.194%) │买入│26.78元百济神州(06160.HK) +5.000 (+6.098%) 沽空 $5.80千万; 比率 34.475% │买入│144.04元华领医药(02552.HK) 0.000 (0.000%) │买入│10.34元药明生物(02269.HK) -0.080 (-0.616%) 沽空 $2.33千万; 比率 5.863% │买入│102.62->139.69元药明康德(02359.HK) -0.200 (-0.581%) 沽空 $1.14千万; 比率 7.699% │买入│115.63->142.37元方达控股(01521.HK) -0.050 (-3.846%) │跑赢大市->买入│5.97元康龙化成(03759.HK) +0.030 (+0.340%) 沽空 $90.59万; 比率 4.954% │买入│53.69->68.25元国药(01099.HK) +0.700 (+3.349%) 沽空 $2.61千万; 比率 16.060% │买入│38.69元华润医药(03320.HK) +0.120 (+2.521%) 沽空 $76.41万; 比率 2.230% │买入│14.21元上海医药(02607.HK) +0.060 (+0.538%) 沽空 $2.10百万; 比率 18.992% │买入│24.04元锦欣生殖(01951.HK) +0.080 (+3.333%) 沽空 $95.95万; 比率 3.433% │跑赢大市->买入│15.37元 (sw/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-24 16:25。)